Combined Magnetic Hyperthermia and Immune Therapy for Primary and Metastatic Tumor Treatments

• Published in: ACS nano Vol. 14; no. 1; pp. 1033 - 1044
• Main Authors: Pan, Jiong, Hu, Ping, Guo, Yuedong, Hao, Junnian, Ni, Dalong, Xu, Yingying, Bao, Qunqun, Yao, Heliang, Wei, Chenyang, Wu, Qingsheng, Shi, Jianlin
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 28-01-2020
• Subjects: Animals; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Cell Survival - drug effects; Cells, Cultured; Cobalt - chemistry; Cobalt - pharmacology; Female; Ferric Compounds - chemistry; Ferric Compounds - pharmacology; Humans; Hyperthermia, Induced; Immunotherapy; Magnetic Phenomena; Manganese Compounds - chemistry; Manganese Compounds - pharmacology; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles - chemistry; Neoplasms, Experimental - pathology; Neoplasms, Experimental - therapy; Particle Size; Surface Properties; cancer; bilateral tumor model; magnetic hyperthermia therapy; checkpoint blockade immunotherapy; core−shell structure
• ISSN: 1936-0851; 1936-086X
• DOI: 10.1021/acsnano.9b08550

Cancer immunotherapy shows promising potential in future cancer treatment but unfortunately is clinically unsatisfactory due to the low therapeutic efficacy and the possible severe immunotoxicity. Here we show a combined magnetic hyperthermia therapy (MHT) and checkpoint blockade immunotherapy for both primary tumor ablation and mimetic metastatic tumor inhibition. Monodispersed, high-performance superparamagnetic CoFe2O4@MnFe2O4 nanoparticles were synthesized and used for effective MHT-induced thermal ablation of primary tumors. Simultaneously, numerous tumor-associated antigens were produced to promote the maturation and activation of dendritic cells (DCs) and cytotoxic T cells for effective immunotherapy of distant mimetic metastatic tumors in a tumor-bearing mice model. The combined MHT and checkpoint blockade immunotherapy demonstrate the great potentials in the fight against both primary and metastatic tumors.